TAG advocacy brief
Drug-sensitive TB treatment can be shortened from six to four months by replacing rifampicin with rifapentine and ethambutol with moxifloxacin. For people with TB, shortening the time on treatment by a third means less time away from work or school, a faster return to life without TB, and fewer healthcare visits and lower out-of-pocket costs along the way. The World Health Organization endorsed the four-month “HPMZ” (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen in 2021, but its use remains limited.
Treatment Action Group (TAG) released an advocacy brief reviewing barriers to the adoption of the four-month regimen and how they might be addressed, and offering a narrative framework communities can use to advocate for the regimen in Global Fund Grant Cycle 8 and beyond.
Access the advocacy brief here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #20, 17 July 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Treatment Action Group
Related HIV and Co-Infections News
-
WHO releases implementation FAQs to accelerate uptake of new TB diagnostic recommendations
-
[Advocacy report] Results UK: Fuelling the fight against the spread of TB: Nutrition is the missing ingredient
-
Gates Medical Research Institute and the Serum Institute of India reach agreement for the manufacture of M72/AS01E TB vaccine candidate, pending successful Phase 3 outcomes
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.